MA43758A - Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés - Google Patents

Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés

Info

Publication number
MA43758A
MA43758A MA043758A MA43758A MA43758A MA 43758 A MA43758 A MA 43758A MA 043758 A MA043758 A MA 043758A MA 43758 A MA43758 A MA 43758A MA 43758 A MA43758 A MA 43758A
Authority
MA
Morocco
Prior art keywords
dosage
determining
methods
therapeutic agent
related treatments
Prior art date
Application number
MA043758A
Other languages
English (en)
Inventor
Yuan Ji
He Li
Original Assignee
Yuan Ji
Juno Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Yuan Ji, Juno Therapeutics Inc filed Critical Yuan Ji
Publication of MA43758A publication Critical patent/MA43758A/fr

Links

Classifications

    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H10/00—ICT specially adapted for the handling or processing of patient-related medical or healthcare data
    • G16H10/20—ICT specially adapted for the handling or processing of patient-related medical or healthcare data for electronic clinical trials or questionnaires
    • G—PHYSICS
    • G06—COMPUTING; CALCULATING OR COUNTING
    • G06N—COMPUTING ARRANGEMENTS BASED ON SPECIFIC COMPUTATIONAL MODELS
    • G06N7/00—Computing arrangements based on specific mathematical models
    • G06N7/01—Probabilistic graphical models, e.g. probabilistic networks
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H20/00—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance
    • G16H20/10—ICT specially adapted for therapies or health-improving plans, e.g. for handling prescriptions, for steering therapy or for monitoring patient compliance relating to drugs or medications, e.g. for ensuring correct administration to patients
    • G—PHYSICS
    • G16—INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR SPECIFIC APPLICATION FIELDS
    • G16H—HEALTHCARE INFORMATICS, i.e. INFORMATION AND COMMUNICATION TECHNOLOGY [ICT] SPECIALLY ADAPTED FOR THE HANDLING OR PROCESSING OF MEDICAL OR HEALTHCARE DATA
    • G16H50/00—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics
    • G16H50/20—ICT specially adapted for medical diagnosis, medical simulation or medical data mining; ICT specially adapted for detecting, monitoring or modelling epidemics or pandemics for computer-aided diagnosis, e.g. based on medical expert systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A90/00—Technologies having an indirect contribution to adaptation to climate change
    • Y02A90/10—Information and communication technologies [ICT] supporting adaptation to climate change, e.g. for weather forecasting or climate simulation

Landscapes

  • Engineering & Computer Science (AREA)
  • Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medical Informatics (AREA)
  • Primary Health Care (AREA)
  • Epidemiology (AREA)
  • General Health & Medical Sciences (AREA)
  • Physics & Mathematics (AREA)
  • Biomedical Technology (AREA)
  • Data Mining & Analysis (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical & Material Sciences (AREA)
  • General Physics & Mathematics (AREA)
  • Theoretical Computer Science (AREA)
  • Databases & Information Systems (AREA)
  • Pathology (AREA)
  • Evolutionary Computation (AREA)
  • Software Systems (AREA)
  • Mathematical Physics (AREA)
  • General Engineering & Computer Science (AREA)
  • Computing Systems (AREA)
  • Pure & Applied Mathematics (AREA)
  • Mathematical Optimization (AREA)
  • Mathematical Analysis (AREA)
  • Computational Mathematics (AREA)
  • Artificial Intelligence (AREA)
  • Algebra (AREA)
  • Probability & Statistics with Applications (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
MA043758A 2016-03-16 2017-03-16 Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés MA43758A (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662309445P 2016-03-16 2016-03-16
US201662321172P 2016-04-11 2016-04-11
US201662371193P 2016-08-04 2016-08-04

Publications (1)

Publication Number Publication Date
MA43758A true MA43758A (fr) 2018-11-28

Family

ID=58461470

Family Applications (1)

Application Number Title Priority Date Filing Date
MA043758A MA43758A (fr) 2016-03-16 2017-03-16 Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés

Country Status (4)

Country Link
US (1) US20190287013A1 (fr)
EP (1) EP3430548A1 (fr)
MA (1) MA43758A (fr)
WO (1) WO2017161208A1 (fr)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG11201703203RA (en) 2014-10-20 2017-05-30 Juno Therapeutics Inc Methods and compositions for dosing in adoptive cell therapy
US11377697B2 (en) 2017-01-11 2022-07-05 Dana-Farber Cancer Institute, Inc. Biomarkers predictive of anti-immune checkpoint response
WO2020146356A1 (fr) * 2019-01-07 2020-07-16 President And Fellows Of Harvard College Techniques d'apprentissage machine pour déterminer des dosages d'agent thérapeutique
WO2021051088A1 (fr) * 2019-09-13 2021-03-18 Ohio State Innovation Foundation Compositions immunothérapeutiques à base de cellules nk, leurs procédés de fabrication et leurs procédés d'utilisation
US12073931B2 (en) * 2022-06-15 2024-08-27 Express Scripts Strategic Development, Inc. Alternate dose regimen identification system

Family Cites Families (41)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4452773A (en) 1982-04-05 1984-06-05 Canadian Patents And Development Limited Magnetic iron-dextran microspheres
US4690915A (en) 1985-08-08 1987-09-01 The United States Of America As Represented By The Department Of Health And Human Services Adoptive immunotherapy as a treatment modality in humans
US4795698A (en) 1985-10-04 1989-01-03 Immunicon Corporation Magnetic-polymer particles
IN165717B (fr) 1986-08-07 1989-12-23 Battelle Memorial Institute
US5219740A (en) 1987-02-13 1993-06-15 Fred Hutchinson Cancer Research Center Retroviral gene transfer into diploid fibroblasts for gene therapy
WO1990007380A2 (fr) 1988-12-28 1990-07-12 Stefan Miltenyi Procedes et matieres pour la separation magnetique a gradient eleve de matieres biologiques
US5200084A (en) 1990-09-26 1993-04-06 Immunicon Corporation Apparatus and methods for magnetic separation
US5827642A (en) 1994-08-31 1998-10-27 Fred Hutchinson Cancer Research Center Rapid expansion method ("REM") for in vitro propagation of T lymphocytes
DE19608753C1 (de) 1996-03-06 1997-06-26 Medigene Gmbh Transduktionssystem und seine Verwendung
US6451995B1 (en) 1996-03-20 2002-09-17 Sloan-Kettering Institute For Cancer Research Single chain FV polynucleotide or peptide constructs of anti-ganglioside GD2 antibodies, cells expressing same and related methods
EP1109921A4 (fr) 1998-09-04 2002-08-28 Sloan Kettering Inst Cancer Recepteurs de fusion specifiques a l'antigene prostatique specifique membranaire et ses utilisations
AU2472400A (en) 1998-10-20 2000-05-08 City Of Hope CD20-specific redirected T cells and their use in cellular immunotherapy of CD20+ malignancies
US20020131960A1 (en) 2000-06-02 2002-09-19 Michel Sadelain Artificial antigen presenting cells and methods of use thereof
AU2001297703B2 (en) 2000-11-07 2006-10-19 City Of Hope CD19-specific redirected immune cells
US7070995B2 (en) 2001-04-11 2006-07-04 City Of Hope CE7-specific redirected immune cells
US20090257994A1 (en) 2001-04-30 2009-10-15 City Of Hope Chimeric immunoreceptor useful in treating human cancers
US7432304B2 (en) * 2001-05-30 2008-10-07 The Regents Of The University Of Michigan Small molecule antagonists of Bcl-2 family proteins
US20030170238A1 (en) 2002-03-07 2003-09-11 Gruenberg Micheal L. Re-activated T-cells for adoptive immunotherapy
US7446190B2 (en) 2002-05-28 2008-11-04 Sloan-Kettering Institute For Cancer Research Nucleic acids encoding chimeric T cell receptors
US20050129671A1 (en) 2003-03-11 2005-06-16 City Of Hope Mammalian antigen-presenting T cells and bi-specific T cells
WO2006060393A2 (fr) * 2004-11-30 2006-06-08 Bg Medicine, Inc. Analyse systemique biologique
CA2682527C (fr) 2007-03-30 2017-07-11 Memorial Sloan-Kettering Cancer Center Expression constitutive de ligands costimulants sur des lymphocytes t transferes de maniere adoptive
JP5616220B2 (ja) * 2007-06-01 2014-10-29 ザ トラスティーズ オブ プリンストン ユニバーシティ 宿主細胞代謝経路の調節によるウイルス感染治療
EP3338895B1 (fr) 2007-12-07 2022-08-10 Miltenyi Biotec B.V. & Co. KG Systèmes et procédés de traitement d'échantillons
US8479118B2 (en) 2007-12-10 2013-07-02 Microsoft Corporation Switching search providers within a browser search box
US20120164718A1 (en) 2008-05-06 2012-06-28 Innovative Micro Technology Removable/disposable apparatus for MEMS particle sorting device
JP5173594B2 (ja) 2008-05-27 2013-04-03 キヤノン株式会社 管理装置、画像形成装置及びそれらの処理方法
PT3006459T (pt) 2008-08-26 2021-11-26 Hope City Método e composições para funcionamento melhorado de efetores antitumorais de células t
SI2496698T1 (sl) 2009-11-03 2019-07-31 City Of Hope Skrajšan epiderimalni receptor faktorja rasti (EGFRt) za selekcijo transduciranih T celic
SG190997A1 (en) 2010-12-09 2013-07-31 Univ Pennsylvania Use of chimeric antigen receptor-modified t cells to treat cancer
CN106074601A (zh) 2011-03-23 2016-11-09 弗雷德哈钦森癌症研究中心 用于细胞免疫治疗的方法和组合物
US8398282B2 (en) 2011-05-12 2013-03-19 Delphi Technologies, Inc. Vehicle front lighting assembly and systems having a variable tint electrowetting element
US10208086B2 (en) 2011-11-11 2019-02-19 Fred Hutchinson Cancer Research Center Cyclin A1-targeted T-cell immunotherapy for cancer
JP6850528B2 (ja) 2012-02-13 2021-03-31 シアトル チルドレンズ ホスピタル ドゥーイング ビジネス アズ シアトル チルドレンズ リサーチ インスティテュート 二重特異性キメラ抗原受容体およびその治療的使用
WO2013126726A1 (fr) 2012-02-22 2013-08-29 The Trustees Of The University Of Pennsylvania Lymphocytes t doubles transgéniques comportant un car et un tcr, et leurs procédés d'utilisation
US9751928B2 (en) 2012-05-03 2017-09-05 Fred Hutchinson Cancer Research Center Enhanced affinity T cell receptors and methods for making the same
RU2700765C2 (ru) 2012-08-20 2019-09-19 Фред Хатчинсон Кансэр Рисёч Сентер Способ и композиции для клеточной иммунотерапии
WO2014055668A1 (fr) 2012-10-02 2014-04-10 Memorial Sloan-Kettering Cancer Center Compositions et procédés d'immunothérapie
WO2014097442A1 (fr) 2012-12-20 2014-06-26 三菱電機株式会社 Dispositif embarqué et programme
TWI654206B (zh) 2013-03-16 2019-03-21 諾華公司 使用人類化抗－ｃｄ１９嵌合抗原受體治療癌症
US9108442B2 (en) 2013-08-20 2015-08-18 Ricoh Company, Ltd. Image forming apparatus

Also Published As

Publication number Publication date
WO2017161208A1 (fr) 2017-09-21
EP3430548A1 (fr) 2019-01-23
US20190287013A1 (en) 2019-09-19

Similar Documents

Publication Publication Date Title
MA43758A (fr) Procédés pour déterminer le dosage d'un agent thérapeutique et traitements associés
MA50082A (fr) Inhibiteurs d'enpp1 et leur utilisation pour le traitement du cancer
MA55697A (fr) Molécules d'anticorps pour le traitement du cancer
MA50849A (fr) Substances et procédés pour le traitement d'hémoglobinopathies
MA54609A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA42043A (fr) Anticorps anti-ox40 et procédés d'utilisation de ceux-ci
MA47310A (fr) Combinaisons de cabozantinib et d'atzolizumab pour traiter le cancer
MA50636A (fr) Compositions et procédés pour inhiber l'activité d'arginase
MA47208A (fr) Procédés de traitement du cancer à l'aide d'anticorps anti-pd-1
MA42819A (fr) Procédés pour le traitement d'infections virales à arenaviridae et coronaviridae
MA43283A (fr) Procédés et compositions pour le traitement du cancer
MA51552A (fr) Anticorps anti-ox40 et procédés d'utilisation
MA54608A (fr) Inhibiteurs aza-hétérobicycliques de mat2a et procédés d'utilisation pour le traitement du cancer
MA42420A (fr) Vaccins pour le traitement et la prévention du cancer
MA45798A (fr) Compositions et procédés d'inhibition de masp-3 pour le traitement de maladies et troubles divers
MA42439A (fr) Agents, utilisations et procédés pour le traitement d'une synucléinopathie
MA40008A (fr) Antagoniste actrii pour le traitement et la prevention d'un ulcere cutane chez un sujet ayant l'anemie
MA46791A (fr) Composés et procédés pour réduire l'expression d'atxn3
SI3442578T1 (sl) Postopki za določanje in doseganje terapevtsko učinkovitih odmerkov sredstev proti CD47 pri zdravljenju raka
MA43170A (fr) Association d'un inhibiteur de bcl-2 et d'un inhibiteur de mek pour le traitement du cancer
MA45865A (fr) Procédés de détection et de traitement d'une tumeur exprimant pt346 pdk1
MA43274A (fr) Gilet portable pour l'application de thérapie pulmonaire et procédé associé
MA46621A (fr) Traitements combinés comprenant l'administration d'imidazopyrazinones
IL278889A (en) Dosing regimen for the treatment of PI3K-related disorders
MA44700A (fr) Combinaison d'un anticorps anti-il-10 et d'un oligonucléotide de type cpg-c pour le traitement du cancer